Strategies to Reduce Addiction Stigma Among Health Professionals
8. november 2021 opdateret af: Johns Hopkins Bloomberg School of Public Health
Effect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Professionals: A Randomized Experiment
The aim of this study was to evaluate the effects of exposure to stigma reduction message frames communicated by visual campaigns and narrative vignettes among a national sample of health professionals.
Studieoversigt
Status
Afsluttet
Intervention / Behandling
- Adfærdsmæssigt: Words Matter - Visual Campaign
- Adfærdsmæssigt: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Adfærdsmæssigt: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Adfærdsmæssigt: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
- Adfærdsmæssigt: Medication Treatment for Opioid Use Disorder Works - Visual Campaign
- Adfærdsmæssigt: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
- Adfærdsmæssigt: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Adfærdsmæssigt: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Detaljeret beskrivelse
This randomized experiment evaluated the impact of exposure to message frames communicating the importance of non-stigmatizing language regarding addiction and the effectiveness of medication treatment for opioid use disorder delivered through a visual campaign alone or through a visual campaign in addition to a narrative vignette from the perspective of one of three messengers (a person with opioid use disorder, a clinician, or a health system leader) on attitudes toward people with opioid use disorder and medications for treating opioid use disorder among a national sample of health professionals.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
1842
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21205
- Johns Hopkins Bloomberg School of Public Health
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- employed as health professional in the United States, including clinicians (e.g., physicians, nurses, physician assistants, pharmacists, and optometrists), technicians and technologists (e.g., laboratory technologist or technician, emergency medical technician, paramedic, licensed practical or licensed vocational nurse, medical records or health information technician, etc.), health aids and assistants (e.g., nursing aide, home health aide, medical assistant, pharmacy aide, phlebotomist, etc.)
- participant in existing web-based survey panel (IPSOS's KnowledgeNetworks panel and partner opt-in panel)
Exclusion Criteria:
- not employed in health profession
- not able to complete experiment and survey in English
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: No exposure control group
This group was not exposed to any message frame.
|
|
|
Eksperimentel: Words Matter - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
|
|
Eksperimentel: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
|
|
Eksperimentel: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
|
|
Eksperimentel: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
|
|
Eksperimentel: Medication Treatment Works - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
|
|
Eksperimentel: Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
|
|
Eksperimentel: Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
|
|
Eksperimentel: Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Rating of willingness to have person with opioid use disorder marry into their family
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder marry into the family.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person with opioid use disorder as a neighbor
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder as a neighbor.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that opioid use disorder is a medical condition
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Opioid use disorder is a chronic medical condition like diabetes mellitus" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that individuals with opioid use disorder are to blame
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Individuals with opioid use disorder only have themselves to blame for their problem" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of support for increasing government spending on opioid use disorder treatment
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of support for increasing government spending on treatment of opioid use disorder with 5 indicating strongly favoring and 1 indicating strongly opposing.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Feeling thermometer measure of warmth toward people with opioid use disorder
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of warmth felt toward people with opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Stigmatizing Language - Addict
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "addict" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - Substance abuse
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "substance abuse" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - dirty
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "'dirty' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - clean
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "'clean' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - addicted baby
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "addicted baby" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - person with substance use disorder
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "person with substance use disorder" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - substance use
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "substance use" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - negative test result
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "negative test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - positive test result
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "positive test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - baby born with neonatal opioid withdrawal syndrome
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "baby born with neonatal opioid withdrawal syndrome" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Willingness to sign pledge committing to using non-stigmatizing language
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Binary (yes/no) measure of whether participant is willing to sign a pledge committing to using non-stigmatizing language related to substance use disorder in clinical settings.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Perception of opioid use disorder treatment effectiveness
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Participant perception of whether there is a treatment for opioid use disorder that is effective for a long period of time (three close-ended response options: yes, there is a treatment; no, there isn't such a treatment; don't know).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person taking medication marry into their family
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of willingness to have person taking medication to treat opioid use disorder marry into family.
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder marry into the family.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person taking medication marry as a neighbor
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of willingness to have person taking medication to treat opioid use disorder as a neighbor.
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder as a neighbor.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of strength/weakness of person taking medication
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of strength/weakness of person taking medication to treat opioid use disorder on 5-point Likert scale with 5 indicating strong and 1 indicating weak.
This is a semantic differential measure.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that recovery is possible
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Most people with opioid use disorder will, with medication treatment, get well and return to productive lives" on a 5-point Likert scale with 5 indicating strongly disagree and 1 indicating strongly agree.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Feeling thermometer measure of warmth toward people taking medication
Tidsramme: Measured immediately post-exposure to message frame intervention
|
Rating of warmth felt toward people taking medication to treat opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Alene Kennedy-Hendricks, PhD, Johns Hopkins Bloomberg School of Public Health
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
13. november 2020
Primær færdiggørelse (Faktiske)
30. november 2020
Studieafslutning (Faktiske)
30. november 2020
Datoer for studieregistrering
Først indsendt
28. oktober 2021
Først indsendt, der opfyldte QC-kriterier
8. november 2021
Først opslået (Faktiske)
19. november 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
19. november 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. november 2021
Sidst verificeret
1. november 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Kemisk inducerede lidelser
- Patologiske processer
- Narkotika-relaterede lidelser
- Stof-relaterede lidelser
- Sygdom
- Opioid-relaterede lidelser
- Lægemidlers fysiologiske virkninger
- Depressive midler til centralnervesystemet
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Narkotika
- Analgetika, Opioid
Andre undersøgelses-id-numre
- IRB14743
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .